HomeBlog of Signaling Pathways

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Blog of Signaling Pathways

Interactions between Slit-Robo and JAK-STAT signaling in regulation of stem cell-niche adhesion

8938 views | Nov 10 2014

Rachel R. Stine et al. found Slit-Robo and JAK-STAT signaling pathways play key roles in stem cells competition within their niches. [Read the Full Post]

High-fat diet and NAD+ replenishment can rescue Cockayne Syndrome

5766 views | Nov 07 2014

Scheibye-Knudsen et al. demonstrated high-fat diet, the inhibition of β-OHB, and the elevation of NAD+ levels, may have the effect to rescue CS-associated phenotype through activating SIRT 1 signaling. [Read the Full Post]

FGF21 is not required for CR-mediated IGF-1 reduction or cell proliferation inhibition

8222 views | Nov 06 2014

Thompson et al. found that, in response to moderate CR, phosphorylated STAT5 may act as a key molecule, and FGF21 was not required for the down-regulation of IGF-1 expression level or cell proliferation rates. [Read the Full Post]

New platform of high efficiency iPSC reprogramming

8824 views | Nov 05 2014

Vidal et al. found the inhibition of transforming growth factor β (TGF-β) or activation of Wnt signaling, or both, can provide a high efficient iPSC reprogramming in a cell-type-specific manner. [Read the Full Post]

Targeting ALK and ERK5 is a new strategy for neuroblastoma treatment

4632 views | Nov 04 2014

Umapathy et al. found kinase ERK5 regulates Anaplastic lymphoma kinase (ALK) induced MYCN transcription and proliferation of neuroblastoma. The results indicates that combination therapy of inhibiting ALK and ERK5 may be a novel strategy for ALK-positive neuroblastoma patients. [Read the Full Post]

JAK2 and MPL are two main regulators of TPO-induced megakaryopoiesis

7344 views | Nov 03 2014

Megakaryopoiesis is regulated by TPO, which activates multiple signaling molecules. Besancenot et al. demonstrated that the protein levels of JAK2 and MPL determine TPO-induced megakaryopoiesis. [Read the Full Post]

Huntingtin enhances Huntington's disease via activating mTORC1 signaling pathway

3296 views | Oct 31 2014

Huntington's disease causes muscle discoordination and cognitive decline. This disease is associated with huntingtin protein. William Pryor et al. found huntingtin enhances signaling of mTORC1. [Read the Full Post]

Neural stem cells "heal" target cells via extracellular vesicles

4377 views | Oct 29 2014

Cossetti et al. found NPCs communicate to the host via extracellular vesicles (EVs) and also investigated the cytokine-regulated pathways involved in the communication. It comes to a novel view in the understanding the mechanisms of stem cell therapy. [Read the Full Post]

The role of TGFβ target——LTBP4 in muscular dystrophy

4315 views | Oct 24 2014

Ceco et al. found latent transforming growth factor-β (TGFβ) binding proteins 4 (LTBP4) play determinant roles in muscular dystrophy symptoms.Their data suggested that blocking LTBP4 results in reduced TGFβ release, and then leads to a reduction of muscle inflammation and damage in DMD. [Read the Full Post]

Notch signaling acts as a key regulator in generation of neurons from neural precursor cells

5727 views | Oct 23 2014

Notch signaling plays a central role before asymmetric division and in the fate of Drosophila melanogaster neural precursor cells. It also acts as a critical factor in Numb distribution in neural precursor cells before cleavage. [Read the Full Post]

The effect of panobinostat on HIV latency disruption in a phase 1/2 clinical trial

5864 views | Oct 22 2014

Rasmussen et al. found panobinostat, a histone deacetylase inhibitor, has the ability to activate infected cells from HIV latency. They also tested the safety of this strategy on phase 1/2 clinical trial. The effect of panobinostat treatment was not significant in reducing the number of latently infected cells. However, panobinostat effectively disrupt HIV latency in vivo. [Read the Full Post]

TIPE3, a new transfer protein of lipid second messengers regulates human cancer

2558 views | Oct 21 2014

Svethlana et al. found one of the transfer protein, TIPE3 (TNFAIP8L3), acts as a controller of phosphoinositide second messenger that promotes cancer. IPE3 may represent a valuable target in therapeutic treatment of malignant diseases. [Read the Full Post]

Two side roads toward conquest of HBV

2964 views | May 05 2014

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM. [Read the Full Post]

Copper dependent Cancer

2287 views | Apr 15 2014

Wortmannin is a PI3K with IC50 of 3 nM, first described PI3K inhibitors [Read the Full Post]

How to survive the zombie apocalypse

2874 views | Apr 02 2014

LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. [Read the Full Post]

Is it really that nonselective inhibitors have no future in clinical study

2494 views | Apr 01 2014

R547 is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. [Read the Full Post]

Story of Bcr Abl continues

2588 views | Mar 28 2014

PP242 is a selective mTOR inhibitor with IC50 of 8 nM; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively. [Read the Full Post]

Not all DUBs are equal

3989 views | Mar 21 2014

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. [Read the Full Post]

A small molecule bidentate binding dual inhibitor probe of the LRRK2 and JNK kinases

2454 views | Mar 17 2014

PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM [Read the Full Post]

Maraviroc is an antiretroviral drug in the CCR5 receptor antagonist class

3674 views | Mar 13 2014

Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively. [Read the Full Post]